RP
MCID: RTN008
MIFTS: 80

Retinitis Pigmentosa (RP) malady

Categories: Genetic diseases, Rare diseases, Eye diseases

Aliases & Classifications for Retinitis Pigmentosa

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 35LifeMap Discovery®, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Retinitis Pigmentosa:

Name: Retinitis Pigmentosa 35 11 48 24 25 54 52 70 50 39 13 68
Rod-Cone Dystrophy 48 25 70
Rp 48 25 70
Retinitis Pigmentosa 1 39 68
Retinitis Pigmentosa Autosomal Recessive 70
Pericentral Pigmentary Retinopathy 11
Non-Syndromic Retinitis Pigmentosa 70
 
Retinitis Pigmentosa Syndrome 27
Tapetoretinal Degeneration 25
Pigmentary Retinopathy 25
Cone Rod Dystrophy 54
Rhyns Syndrome 68
Arrp 70
Rcd 70

Characteristics:

Orphanet epidemiological data:

54
retinitis pigmentosa:
Inheritance: Autosomal dominant,Autosomal recessive,Mitochondrial inheritance,X-linked recessive; Prevalence: 1-5/10000 (Europe),1-5/10000 (Worldwide),1-5/10000 (Denmark),1-5/10000 (Norway),1-5/10000 (United States),1-5/10000 (United Kingdom),1-5/10000 (China),1-5/10000 (Slovenia); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy
cone rod dystrophy:
Inheritance: Autosomal dominant,Autosomal recessive,X-linked recessive; Age of onset: Childhood; Age of death: normal life expectancy

Classifications:

Orphanet: 54 
Rare eye diseases


External Ids:

Disease Ontology11 DOID:10584
ICD1030 H35.52
NCIt45 C85045
SNOMED-CT62 155113002, 28835009
ICD10 via Orphanet31 H35.5
MESH via Orphanet40 D012174
UMLS via Orphanet69 C0035334
MedGen37 C0035334
OMIM52 268000

Summaries for Retinitis Pigmentosa

About this section
OMIM:52 Retinitis pigmentosa (RP) refers to a heterogeneous group of inherited ocular diseases that result in a progressive... (268000) more...

MalaCards based summary: Retinitis Pigmentosa, also known as rod-cone dystrophy, is related to retinitis pigmentosa 19 and retinitis pigmentosa 34, and has symptoms including Array, Array and Array. An important gene associated with Retinitis Pigmentosa is CRX (Cone-Rod Homeobox), and among its related pathways are Metabolism of fat-soluble vitamins and Phototransduction. Affiliated tissues include retina, bone and eye, and related mouse phenotypes are Decreased shRNA abundance (Z-score < -2) and nervous system.

NIH Rare Diseases:48 Retinitis pigmentosa (rp) is a group of inherited eye diseases that affect the light-sensitive part of the eye (retina). rp causes cells in the retina to die, causing progressive vision loss. the first sign of rp usually is night blindness. as the condition progresses, affected individuals develop tunnel vision (loss of peripheral vision), and eventually loss of central vision. rp may be caused by mutations in any of at least 50 genes. inheritance can be autosomal dominant, autosomal recessive, or x-linked. treatment options to slow the progression of vision loss include light avoidance, use of low-vision aids, and vitamin a supplementation. researchers are working to develop new treatment options for the future such as gene therapy, stem cell transplantation and prosthetic implants. last updated: 10/18/2016

UniProtKB/Swiss-Prot:70 Retinitis pigmentosa: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

Genetics Home Reference:25 Retinitis pigmentosa is a group of related eye disorders that cause progressive vision loss. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with retinitis pigmentosa, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.

Disease Ontology:11 A retinal degeneration characterized by the gradual deterioration of the photoreceptors or the retinal pigment epithelium of the retina leading to progressive sight loss.

Wikipedia:71 Retinitis pigmentosa (RP) is an inherited, degenerative eye disease that causes severe vision impairment... more...

Related Diseases for Retinitis Pigmentosa

About this section

Diseases in the Retinitis Pigmentosa family:

Retinitis Pigmentosa 59 Retinitis Pigmentosa 20
Retinitis Pigmentosa 19 Retinitis Pigmentosa 32
Retinitis Pigmentosa 18 Retinitis Pigmentosa 35
Retinitis Pigmentosa-12, Autosomal Recessive Retinitis Pigmentosa 67
Retinitis Pigmentosa 39 Retinitis Pigmentosa 58
Retinitis Pigmentosa 54 Retinitis Pigmentosa 71
Retinitis Pigmentosa 28 Retinitis Pigmentosa 33
Retinitis Pigmentosa 38 Retinitis Pigmentosa 26
Retinitis Pigmentosa 47 Retinitis Pigmentosa 55
Retinitis Pigmentosa 56 Retinitis Pigmentosa 4, Autosomal Dominant or Recessive
Retinitis Pigmentosa 61 Retinitis Pigmentosa 68
Retinitis Pigmentosa-40 Retinitis Pigmentosa 41
Retinitis Pigmentosa 49 Retinitis Pigmentosa 29
Retinitis Pigmentosa 43 Retinitis Pigmentosa 62
Retinitis Pigmentosa 14 Retinitis Pigmentosa 48
Retinitis Pigmentosa 25 Retinitis Pigmentosa 63
Retinitis Pigmentosa 42 Retinitis Pigmentosa 9
Retinitis Pigmentosa 10 Retinitis Pigmentosa 73
Retinitis Pigmentosa 1 Retinitis Pigmentosa 31
Retinitis Pigmentosa 70 Retinitis Pigmentosa 66
Retinitis Pigmentosa 44 Retinitis Pigmentosa 72
Retinitis Pigmentosa-50 Retinitis Pigmentosa 27
Retinitis Pigmentosa 51 Retinitis Pigmentosa 37
Retinitis Pigmentosa 22 Retinitis Pigmentosa 45
Retinitis Pigmentosa 74 Retinitis Pigmentosa 13
Retinitis Pigmentosa 36 Retinitis Pigmentosa 17
Retinitis Pigmentosa 30 Retinitis Pigmentosa 57
Retinitis Pigmentosa 11 Retinitis Pigmentosa 46
Retinitis Pigmentosa 69 Retinitis Pigmentosa 60
Retinitis Pigmentosa 23 Retinitis Pigmentosa 3
Retinitis Pigmentosa 2 Retinitis Pigmentosa 24
Retinitis Pigmentosa 34 Retinitis Pigmentosa 75
Late-Adult Onset Retinitis Pigmentosa Nonsyndromic Retinitis Pigmentosa
Bbs2-Related Retinitis Pigmentosa Abca4-Related Retinitis Pigmentosa
Agbl5-Related Retinitis Pigmentosa Aipl1-Related Retinitis Pigmentosa
Arl2bp-Related Retinitis Pigmentosa Arl6-Related Retinitis Pigmentosa
Best1-Related Retinitis Pigmentosa C2orf71-Related Retinitis Pigmentosa
C8orf37-Related Retinitis Pigmentosa Ca4-Related Retinitis Pigmentosa
Cerkl-Related Retinitis Pigmentosa Clrn1-Related Retinitis Pigmentosa
Cnga1-Related Retinitis Pigmentosa Cngb1-Related Retinitis Pigmentosa
Crb1-Related Retinitis Pigmentosa Crx-Related Retinitis Pigmentosa
Dhdds-Related Retinitis Pigmentosa Eys-Related Retinitis Pigmentosa
Fam161a-Related Retinitis Pigmentosa Fscn2-Related Retinitis Pigmentosa
Guca1b-Related Retinitis Pigmentosa Idh3b-Related Retinitis Pigmentosa
Impdh1-Related Retinitis Pigmentosa Impg2-Related Retinitis Pigmentosa
Kiz-Related Retinitis Pigmentosa Klhl7-Related Retinitis Pigmentosa
Lrat-Related Retinitis Pigmentosa Mak-Related Retinitis Pigmentosa
Mertk-Related Retinitis Pigmentosa Nr2e3-Related Retinitis Pigmentosa
Nrl-Related Retinitis Pigmentosa Ofd1-Related Retinitis Pigmentosa
Pde6a-Related Retinitis Pigmentosa Pde6b-Related Retinitis Pigmentosa
Pde6g-Related Retinitis Pigmentosa Prcd-Related Retinitis Pigmentosa
Prom1-Related Retinitis Pigmentosa Prpf3-Related Retinitis Pigmentosa
Prpf31-Related Retinitis Pigmentosa Prpf4-Related Retinitis Pigmentosa
Prpf6-Related Retinitis Pigmentosa Prpf8-Related Retinitis Pigmentosa
Prph2-Related Retinitis Pigmentosa Rbp3-Related Retinitis Pigmentosa
Rdh12-Related Retinitis Pigmentosa Rgr-Related Retinitis Pigmentosa
Rho-Related Retinitis Pigmentosa Rom1-Related Retinitis Pigmentosa
Rp1-Related Retinitis Pigmentosa Rp2-Related Retinitis Pigmentosa
Rp9-Related Retinitis Pigmentosa Rpe65-Related Retinitis Pigmentosa
Rpgr-Related Retinitis Pigmentosa Sag-Related Retinitis Pigmentosa
Sema4a-Related Retinitis Pigmentosa Slc7a14-Related Retinitis Pigmentosa
Snrnp200-Related Retinitis Pigmentosa Spata7-Related Retinitis Pigmentosa
Topors-Related Retinitis Pigmentosa Ttc8-Related Retinitis Pigmentosa
Tulp1-Related Retinitis Pigmentosa Ush2a-Related Retinitis Pigmentosa
Znf513-Related Retinitis Pigmentosa Retinitis Pigmentosa 76
Retinitis Pigmentosa 77

Diseases related to Retinitis Pigmentosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 432)
idRelated DiseaseScoreTop Affiliating Genes
1retinitis pigmentosa 1934.2ABCA4, CRX, RHO, ROM1
2retinitis pigmentosa 3434.0ABCA4, RHO, RPE65
3vitreoretinochoroidopathy33.2ABCA4, BEST1, PRPH2, ROM1
4cone-rod dystrophy 331.8ABCA4, PDE6B
5newfoundland rod-cone dystrophy12.6
6retinitis pigmentosa 312.4
7retinitis pigmentosa 212.3
8retinitis pigmentosa 912.3
9retinitis pigmentosa 112.3
10retinitis pigmentosa 1712.3
11retinitis pigmentosa 2812.3
12polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract12.2
13neuropathy, ataxia, and retinitis pigmentosa12.2
14retinitis pigmentosa 7 and digenic12.2
15ataxia, posterior column, with retinitis pigmentosa12.2
16retinitis pigmentosa 3812.2
17retinitis pigmentosa 1112.2
18retinitis pigmentosa 1412.2
19retinitis pigmentosa 6712.2
20retinitis pigmentosa 6912.2
21retinitis pigmentosa 2012.2
22retinitis pigmentosa 1812.2
23retinitis pigmentosa 3512.2
24retinitis pigmentosa 3312.2
25retinitis pigmentosa 2612.2
26retinitis pigmentosa 4, autosomal dominant or recessive12.2
27retinitis pigmentosa 4112.2
28retinitis pigmentosa 2512.2
29retinitis pigmentosa 3112.2
30retinitis pigmentosa 1312.2
31retinitis pigmentosa 3612.2
32retinitis pigmentosa 3012.2
33retinitis pigmentosa 5912.2
34retinitis pigmentosa 5812.2
35retinitis pigmentosa 4712.2
36retinitis pigmentosa 5512.2
37retinitis pigmentosa 4912.2
38retinitis pigmentosa 4312.2
39retinitis pigmentosa 6212.2
40retinitis pigmentosa 4812.2
41retinitis pigmentosa 4212.2
42retinitis pigmentosa 1012.2
43retinitis pigmentosa 4412.2
44retinitis pigmentosa 2712.2
45retinitis pigmentosa 5112.2
46retinitis pigmentosa 4512.2
47retinitis pigmentosa 4612.2
48retinitis pigmentosa 6012.2
49retinitis pigmentosa 2312.2
50retinitis pigmentosa 7512.1

Graphical network of the top 20 diseases related to Retinitis Pigmentosa:



Diseases related to retinitis pigmentosa

Symptoms & Phenotypes for Retinitis Pigmentosa

About this section

Symptoms by clinical synopsis from OMIM:

268000

Clinical features from OMIM:

268000

Human phenotypes related to Retinitis Pigmentosa:

 54 64 (show all 31)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the testis64 54 Very frequent (99-80%) HP:0000035
2 hypogonadism64 54 Very frequent (99-80%) HP:0000135
3 conductive hearing impairment64 54 Very frequent (99-80%) HP:0000405
4 sensorineural hearing impairment64 54 Very frequent (99-80%) HP:0000407
5 wide nasal bridge64 54 Very frequent (99-80%) HP:0000431
6 anteverted nares64 54 Very frequent (99-80%) HP:0000463
7 glaucoma64 54 Frequent (79-30%) HP:0000501
8 visual impairment54 Very frequent (99-80%)
9 abnormal electroretinogram64 54 Very frequent (99-80%) HP:0000512
10 cataract64 54 Frequent (79-30%) HP:0000518
11 keratoconus64 54 Frequent (79-30%) HP:0000563
12 ophthalmoplegia64 54 Frequent (79-30%) HP:0000602
13 photophobia64 54 Very frequent (99-80%) HP:0000613
14 blindness64 54 Very frequent (99-80%) HP:0000618
15 nystagmus64 54 Very frequent (99-80%) HP:0000639
16 optic atrophy64 54 Very frequent (99-80%) HP:0000648
17 hyperinsulinemia64 54 Frequent (79-30%) HP:0000842
18 atypical scarring of skin64 54 Very frequent (99-80%) HP:0000987
19 intellectual disability64 54 Very frequent (99-80%) HP:0001249
20 hyperreflexia64 54 Occasional (29-5%) HP:0001347
21 obesity64 54 Frequent (79-30%) HP:0001513
22 type ii diabetes mellitus64 54 Occasional (29-5%) HP:0005978
23 progressive night blindness64 54 Very frequent (99-80%) HP:0007675
24 abnormality of retinal pigmentation64 54 Very frequent (99-80%) HP:0007703
25 abnormality of the retinal vasculature64 54 Very frequent (99-80%) HP:0008046
26 hypoplasia of penis64 54 Very frequent (99-80%) HP:0008736
27 abnormality of color vision54 Frequent (79-30%)
28 night blindness54 Very frequent (99-80%)
29 rod-cone dystrophy64 HP:0000510
30 nyctalopia64 HP:0000662
31 constriction of peripheral visual field64 HP:0001133

GenomeRNAi Phenotypes related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-8411.5EYS, PDE6B, TOPORS

MGI Mouse Phenotypes related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000363112.4ABCA4, C2orf71, CRB1, CRX, PDE6B, PRPH2
2MP:000118612.2ABCA4, BEST1, C2orf71, CRB1, CRX, PDE6B
3MP:000538512.1ABCA4, CRX, PDE6B, PRPH2, RHO, ROM1
4MP:000539111.8ABCA4, BEST1, C2orf71, CRB1, CRX, PDE6B

Drugs & Therapeutics for Retinitis Pigmentosa

About this section

Drugs for Retinitis Pigmentosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 115)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Vitamin Aapproved, nutraceutical, vet_approvedPhase 3, Phase 149211103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
2
Luteinapproved, nutraceuticalPhase 3, Phase 1, Phase 271127-40-26433159, 5368396
Synonyms:
(3R,3'R)-beta,beta-Carotene-3,3'-Diol, Lutein
(3R,3'R,6'R)-Lutein
(3R,3'R,6S)-4,5-Didehydro-5,6-Dihydro-beta,beta-Carotene-3,3'-Diol
3,3'-Dihydroxy-alpha-carotene
4,5-Didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol
All-trans-(+)-Xanthophyll
All-trans-Lutein
All-trans-Xanthophyll
 
Bo-Xan
Lutein
Lutein ester
Luteine
Phylloxanthin
Vegetable lutein
Vegetable luteol
beta,epsilon-Carotene-3,3'-diol
trans-Lutein
3
Vitamin Eapproved, nutraceutical, vet_approvedPhase 341459-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
4VitaminsPhase 3, Phase 2, Phase 1, Early Phase 15282
5Antihypertensive AgentsPhase 3, Phase 1, Phase 24207
6TocopherolsPhase 3414
7MicronutrientsPhase 3, Phase 2, Phase 1, Early Phase 16001
8vitamin dPhase 31724
9Bone Density Conservation AgentsPhase 33376
10Protective AgentsPhase 3, Phase 2, Phase 17443
11AntioxidantsPhase 3, Phase 2, Phase 13050
12Retinol palmitatePhase 3, Phase 1492
13Trace ElementsPhase 3, Phase 2, Phase 1, Early Phase 16001
14TocotrienolsPhase 3410
15CarotenoidsPhase 2, Phase 3, Phase 1155
16Isopropyl unoprostonePhase 32
17retinolNutraceuticalPhase 3, Phase 1492
18TocopherolNutraceuticalPhase 3414
19TocotrienolNutraceuticalPhase 3410
20Beta CaroteneNutraceuticalPhase 2, Phase 3, Phase 167
21
EphedrineapprovedPhase 1, Phase 2628299-42-39294
Synonyms:
( )-Pseudoephedrine
(+)-Ephedrin
(+)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(+-)-Ephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
--EPHEDRINE
1-EPHEDRINE
1-Sedrin
134910_ALDRICH
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50-98-6
50906-05-3
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC-20231
AC-20292
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AI3-02761
AKOS000268842
AR-1A0126
AR-1I7143
Acunaso
Acunaso (TN)
Afrinol
Ambap299-42-3
BIDD:GT0817
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
Benylin Decongestant
Besan
Biophedrin
C01575
C02765
C10H15NO
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
Cenafed
D00124
D08449
DB00852
DB01364
Decofed
DivK1c_000181
DivK1c_000451
DivK1c_000461
Drixoral N.D.
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eciphin
Efedrin
Efidac/24
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine l-form
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
Fedrin
Genaphed
HSDB 3072
HSDB 3177
I-Sedrin
I01-3584
I01-8925
I01-8928
 
IDI1_000181
IDI1_000451
IDI1_000461
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
KST-1A9168
Kratedyn
L(+)-psi-Ephedrine
L(-)-Ephedrine
L-(+)-Ephedrine
L-(-)-Ephedrine
L-Ephedrine
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
L000968
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Lexofedrin
Lopac-E-3250
Lopac0_000501
MLS000069657
Manadrin
Mandrin
Maxenal
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI-C55652
NCI60_002955
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Nasol
Neodurasina
Neodurasina (TN)
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
Robidrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
ST023802
STK367993
STOCK1N-42675
Sanedrine
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
Spectrum_000878
Spectrum_001020
Sudafed
Sudafed Decongestant
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
d-Ephedrine
d-Isoephedrine
d-Pseudoephedrine
d-psi-Ephedrine
l-Ephedrine
l-Pseudoephedrine
racephedrine
trans-Ephedrine
22
PseudoephedrineapprovedPhase 1, Phase 262890-82-47028
Synonyms:
( )-Pseudoephedrine
(+) threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC-20292
AC1L1NUA
Acunaso
Acunaso (TN)
Afrinol
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
C02765
C10H15NO
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
Cenafed
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-Ephedrine
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
DivK1c_000451
Drixoral N.D.
Drixoral Nasal Decongestant
EINECS 202-018-6
Efidac 24 Pseudoephedrine Hcl
Efidac/24
Eltor 120
Ephedrine
Genaphed
HSDB 3177
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
 
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L(+)-Psi-Ephedrine
L(+)-psi-Ephedrine
L-(+)-Pseudoephedrine
LS-125922
Lopac-E-3250
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
NINDS_000451
Neodurasina
Neodurasina (TN)
Novafed
PDSP1_001347
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
Pseudoephedrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine D-form
Pseudoephedrine Ephedrine
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
STOCK1N-42675
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
Spectrum_000878
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
alpha-(1-(Methylamino)ethyl)benzyl alcohol
d-Isoephedrine
d-Pseudoephedrine
d-psi-2-Methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
pseudoéphédrine
trans-Ephedrine
ψ-ephedrine
23
Minocyclineapproved, investigationalPhase 1, Phase 223110118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline HCl
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
NCGC00178854-01
NSC 141993
NSC141993
Novo-Minocycline
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
24
Povidone-iodineapprovedPhase 2, Phase 116925655-41-8
Synonyms:
 
Betadine
25
Valproic Acidapproved, investigationalPhase 232799-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
26
Ciprofloxacinapproved, investigationalPhase 2, Phase 123685721-33-12764
Synonyms:
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
17850_FLUKA
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
33434_FLUKA
33434_RIEDEL
85721-33-1
AC-7613
AC1L1EEW
AKOS000269653
ARONIS020379
Alcon Cilox
BAS 06989041
BAY q 3939
BAY-Q-3939
BAYQ3939
BIDD:GT0205
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
Bacquinor
Baflox
Bay o 9867
Bay o 9867 (*Hydrochloride*)
Bay-09867
Baycip
Bernoflox
Bi-Cipro
Bio-0540
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
CPF
CPFX
CRL-1605 & Ciprofloxacin
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin hydrochloride
Ciprofloxacin monohydrochloride
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
Ciprofloxacino
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
 
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
LS-141563
Liposomal-ciprofloxacin
Loxan
MLS001336035
MolPort-000-819-654
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
SMP1_000125
SMR000471901
SPBio_001474
SPBio_002065
SPECTRUM1503614
STK021082
Septicide
Sophixin Ofteno
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spectrum_000162
Spitacin
Superocin
UNII-5E8K9I0O4U
Unex
Velomonit
Zumaflox
ciprofloxacin
nchembio820-comp1
27
CarbidopaapprovedPhase 218428860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
28
DopamineapprovedPhase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
29
LevodopaapprovedPhase 240259-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
30
AdapaleneapprovedPhase 1, Phase 277106685-40-960164
Synonyms:
106685-40-9
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
AC-1974
AC1L1SOH
AC1Q5USH
ADAPALENE
AKOS005145841
Adaferin
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
Ambap106685-40-9
BIDD:GT0264
C28H28O3
CD 271
CD-271
CD271
 
CHEBI:217732
CHEBI:31174
CHEMBL1265
CHEMBL76401
CID60164
CPD000466349
D01112
DB00210
Differin
Differin (TN)
Differin, Adapalene
Differine
I06-0642
KS-1196
LS-172017
MLS000759463
MolPort-003-986-211
MolPort-006-823-940
NCGC00164617-01
S1276_Selleck
SAM001246663
SMR000466349
TL8000241
UNII-1L4806J2QF
31
Dexamethasoneapproved, investigational, vet_approvedPhase 2217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
32Anti-Infective AgentsPhase 1, Phase 222062
33Vasoconstrictor AgentsPhase 1, Phase 22122
34Peripheral Nervous System AgentsPhase 1, Phase 223689
35Pharmaceutical SolutionsPhase 1, Phase 28192
36Ophthalmic SolutionsPhase 1, Phase 21140
37Nasal DecongestantsPhase 1, Phase 2598
38Autonomic AgentsPhase 1, Phase 210150
39MitogensPhase 1, Phase 21617
40TetrahydrozolinePhase 1, Phase 2621
41Respiratory System AgentsPhase 1, Phase 24997
42Adjuvants, ImmunologicPhase 2, Phase 12554
43Brimonidine TartratePhase 1, Phase 212570359-46-5
44Adrenergic alpha-AgonistsPhase 1, Phase 21734
45Adrenergic alpha-2 Receptor AgonistsPhase 1, Phase 2980
46Antimanic AgentsPhase 2814
47AnticonvulsantsPhase 22695
48PovidonePhase 2, Phase 1169
49cadexomer iodinePhase 2, Phase 1537
50ProxymetacainePhase 2, Phase 140

Interventional clinical trials:

(show top 50)    (show all 127)
idNameStatusNCT IDPhase
1The Role of Capsular Tension Ring (CTR) in Anterior Capsular ContractionCompletedNCT00717080Phase 4
2Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin ACompletedNCT00346333Phase 3
3Randomized Trial for Retinitis PigmentosaCompletedNCT00000116Phase 3
4Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaCompletedNCT00000114Phase 3
5The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella BardawilRecruitingNCT01680510Phase 2, Phase 3
6Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of ObesityRecruitingNCT03013543Phase 2, Phase 3
7Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaTerminatedNCT01786395Phase 3
8Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis PigmentosaUnknown statusNCT01914913Phase 1, Phase 2
9A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)Unknown statusNCT02110225Phase 1, Phase 2
10Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01560715Phase 2
11Trial of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01233609Phase 2
12A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaCompletedNCT00447993Phase 2
13Safety Study in Retinal Transplantation for Retinitis Pigmentosa.CompletedNCT00345917Phase 2
14Effects of Lutein in Retinitis PigmentosaCompletedNCT00029289Phase 1, Phase 2
15A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaCompletedNCT00447980Phase 2
16Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis PigmentosaCompletedNCT02140164Phase 1, Phase 2
17DHA and X-Linked Retinitis PigmentosaCompletedNCT00100230Phase 2
18An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis PigmentosaCompletedNCT00661479Phase 1, Phase 2
19Efficacy and Safety of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01399515Phase 2
20Feasibility Study of a Chronic Retinal Stimulator in Retinitis PigmentosaCompletedNCT00279500Phase 1, Phase 2
21Studying a Potential Protective Effect of L-Dopa on Retinitis PigmentosaRecruitingNCT02837640Phase 2
22Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium BarbarumRecruitingNCT02244996Phase 2
23Safety and Tolerability of hRPC in Retinitis PigmentosaRecruitingNCT02464436Phase 1, Phase 2
24A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis PigmentosaRecruitingNCT03116113Phase 1, Phase 2
25RST-001 Phase I/II Trial for Retinitis PigmentosaRecruitingNCT02556736Phase 1, Phase 2
26Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BRecruitingNCT01505062Phase 1, Phase 2
27Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis PigmentosaRecruitingNCT03073733Phase 2
28Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström SyndromeRecruitingNCT02739217Phase 2
29Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyActive, not recruitingNCT02661711Phase 2
30Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for the Treatment of Vision Loss Due to Retinitis PigmentosaActive, not recruitingNCT02086890Phase 1, Phase 2
31Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis PigmentosaActive, not recruitingNCT02320812Phase 1, Phase 2
32Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaActive, not recruitingNCT02609165Phase 2
33Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaActive, not recruitingNCT01530659Phase 2
34Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis PigmentosaActive, not recruitingNCT02709876Phase 1, Phase 2
35Argus® II Retinal Stimulation System Feasibility ProtocolActive, not recruitingNCT00407602Phase 2
36Gene Therapy for Blindness Caused by ChoroideremiaActive, not recruitingNCT01461213Phase 1, Phase 2
37Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective StudyEnrolling by invitationNCT02804360Phase 2
38A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1BEnrolling by invitationNCT02065011Phase 1, Phase 2
39The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis PigmentosaNot yet recruitingNCT02018692Phase 1, Phase 2
40Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)SuspendedNCT02338973Phase 1, Phase 2
41Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis PigmentosaUnknown statusNCT01531348Phase 1
42Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01068561Phase 1
43Acupuncture for the Treatment of Vision Loss Due to Retinitis PigmentosaCompletedNCT01604356Phase 1
44Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis PigmentosaCompletedNCT02280135Phase 1
45Investigating the Effect of Vitamin A Supplementation on Retinitis PigmentosaCompletedNCT00065455Phase 1
46Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)CompletedNCT01543906Phase 1
47Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeCompletedNCT00063765Phase 1
48Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)CompletedNCT01521793Phase 1
49Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) MutationsCompletedNCT01014052Phase 1
50The FIGHT-RP1 StudyRecruitingNCT03063021Phase 1

Search NIH Clinical Center for Retinitis Pigmentosa

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinitis Pigmentosa cell therapies at LifeMap Discovery.

Genetic Tests for Retinitis Pigmentosa

About this section

Genetic tests related to Retinitis Pigmentosa:

id Genetic test Affiliating Genes
1 Retinitis Pigmentosa27 24 ZNF513

Anatomical Context for Retinitis Pigmentosa

About this section

MalaCards organs/tissues related to Retinitis Pigmentosa:

36
Retina, Bone, Eye, Testes, Skin, Testis, Kidney

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Retinitis Pigmentosa:
id TissueAnatomical CompartmentCell Relevance
1 EyeOuter Nuclear LayerCone Precursor Cells Potential therapeutic candidate, affected by disease
2 EyeOuter Nuclear LayerMature L Cone Cells Potential therapeutic candidate, affected by disease
3 EyeOuter Nuclear LayerMature M Cone Cells Potential therapeutic candidate, affected by disease
4 EyeOuter Nuclear LayerMature M-S Cone Cells Potential therapeutic candidate, affected by disease
5 EyeRetinal Pigmented EpitheliumMature Retinal Pigmented Epithelium Cells Potential therapeutic candidate, affected by disease
6 EyeOuter Nuclear LayerMature Rod Cells Potential therapeutic candidate, affected by disease
7 EyeOuter Nuclear LayerMature S Cone Cells Potential therapeutic candidate, affected by disease
8 EyeRetinal Pigmented EpitheliumRetinal Pigmented Epithelium Progenitor Cells Potential therapeutic candidate, affected by disease
9 EyeOuter Nuclear LayerRod Precursor Cells Potential therapeutic candidate, affected by disease

Publications for Retinitis Pigmentosa

About this section

Articles related to Retinitis Pigmentosa:

(show top 50)    (show all 1415)
idTitleAuthorsYear
1
A novel mutation in the dominantly inherited TOPORS gene supports haploinsufficiency as the mechanism of retinitis pigmentosa. (28453362)
2017
2
Whole-Exome Sequencing Identifies Biallelic IDH3A Variants as a Cause of Retinitis Pigmentosa Accompanied by Pseudocoloboma. (28412069)
2017
3
Identification of a disease-causing mutation in a Chinese patient with retinitis pigmentosa by targeted next-generation sequencing. (28430325)
2017
4
Whole exome sequencing identified a novel single base pair insertion mutation in the EYS gene in a six generation family with retinitis pigmentosa. (28419563)
2017
5
Clinical Characterization of CNGB1-Related Autosomal Recessive Retinitis Pigmentosa. (28056120)
2017
6
Possible protective role of the ABCA4 gene c.1268A>G missense variant in Stargardt disease and syndromic retinitis pigmentosa in a Sicilian family: Preliminary data. (28290600)
2017
7
Mutation screening in genes known to be responsible for Retinitis Pigmentosa in 98 Small Han Chinese Families. (28512305)
2017
8
Novel variants of RPGR in X-linked retinitis pigmentosa families and genotype-phenotype correlation. (27768226)
2017
9
Type 3 Neovascularization Associated with Retinitis Pigmentosa. (28512428)
2017
10
Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic X. laevis Models of Retinitis Pigmentosa. (28490005)
2017
11
Retinal pigmentary changes in chronic uveitis mimicking retinitis pigmentosa. (28523457)
2017
12
A novel MERTK mutation causing retinitis pigmentosa. (28462455)
2017
13
Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. (27913439)
2017
14
Four-year nationwide incidence of retinitis pigmentosa in South Korea: a population-based retrospective study from 2011 to 2014. (28490561)
2017
15
Mathematical models of retinitis pigmentosa: The oxygen toxicity hypothesis. (28483568)
2017
16
High prevalence of mutations affecting the splicing process in a Spanish cohort with autosomal dominant retinitis pigmentosa. (28045043)
2017
17
Mutations in Splicing Factor Genes Are a Major Cause of Autosomal Dominant Retinitis Pigmentosa in Belgian Families. (28076437)
2017
18
Low dose clozapine controls adult-onset psychosis associated with the neurogenic ataxia-retinitis pigmentosa (NARP) mutation. (28003964)
2017
19
Bilateral blindness with secondary retinitis pigmentosa following postoperative docetaxel and platinum combination chemotherapy in primary small-cell carcinoma of the endometrium: An unusual case report and review of the literature. (28413652)
2017
20
Risk Factors for Posterior Subcapsular Cataract in Retinitis Pigmentosa. (28492871)
2017
21
Pathogenic mutations in retinitis pigmentosa 2 predominantly result in loss of RP2 protein stability in humans and zebrafish. (28209709)
2017
22
Optical Coherence Tomography Angiography to Estimate Retinal Blood Flow in Eyes with Retinitis Pigmentosa. (28406171)
2017
23
Posterior microphthalmos, retinitis pigmentosa and optic disc drusen with white dots. A case report. (28511857)
2017
24
A Nine-Year Follow-Up of Macular Complications in Retinitis Pigmentosa and Diabetes Mellitus. (28419400)
2017
25
Targeted next generation sequencing identified novel mutations in RPGRIP1 associated with both retinitis pigmentosa and Leber's congenital amaurosis in unrelated Chinese patients. (28456785)
2017
26
Seeing through their eyes: lived experiences of people with retinitis pigmentosa. (28085147)
2017
27
Missense mutations in the WD40 domain of AHI1 cause non-syndromic retinitis pigmentosa. (28442542)
2017
28
Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa. (28053051)
2017
29
Genetic rescue models refute nonautonomous rod cell death in retinitis pigmentosa. (28468800)
2017
30
ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. (28451987)
2017
31
Retinitis pigmentosa and bilateral cystoid macular oedema in a patient heterozygous for the RIM1 mutation previously associated with cone-rod dystrophy 7. (27176872)
2016
32
Alterations in glutamate cysteine ligase content in the retina of two retinitis pigmentosa animal models. (27140233)
2016
33
Loss of HCN1 enhances disease progression in mouse models of CNG channel-linked retinitis pigmentosa and achromatopsia. (26740549)
2016
34
Disease mechanisms of X-linked retinitis pigmentosa due to RP2 and RPGR mutations. (27911705)
2016
35
Substantial modifications to retinal architecture occur prior to photoreceptor cell loss in the rd10 mouse model of retinitis pigmentosa. (27160072)
2016
36
Inner segment ellipsoid band length is a prognostic factor in retinitis pigmentosa associated with EYS mutations: 5-year observation of retinal structure. (27564720)
2016
37
A case of hyperhomocysteinemia with retinitis pigmentosa - A rare presentation. (27728730)
2016
38
Course of Ocular Function in PRPF31 Retinitis Pigmentosa. (26959129)
2016
39
Whole exome sequencing identifies a novel NRL mutation in a Chinese family with autosomal dominant retinitis pigmentosa. (27081294)
2016
40
A challenge to the striking genotypic heterogeneity of retinitis pigmentosa: a better understanding of the pathophysiology using the newest genetic strategies. (27564722)
2016
41
Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide. (27521675)
2016
42
Wide-Field Fundus Autofluorescence for Retinitis Pigmentosa and Cone/Cone-Rod Dystrophy. (26427426)
2016
43
Bi-allelic Mutations in KLHL7 Cause a Crisponi/CISS1-like Phenotype Associated with Early-Onset Retinitis Pigmentosa. (27392078)
2016
44
Retinitis Pigmentosa Mutations in Bad Response to Refrigeration 2 (Brr2) Impair ATPase and Helicase Activity. (27072132)
2016
45
Relative Difficulties of Daily Living Tasks with Retinitis Pigmentosa. (28033161)
2016
46
A novel start codon mutation of the MERTK gene in a patient with retinitis pigmentosa. (27122965)
2016
47
Association Between Aqueous Flare and Epiretinal Membrane in Retinitis Pigmentosa. (27548902)
2016
48
Dominant Retinitis Pigmentosa, p.Gly56Arg Mutation in NR2E3: Phenotype in a Large Cohort of 24 Cases. (26910043)
2016
49
Transcriptional regulation of PRPF31 gene expression by MSR1 repeat elements causes incomplete penetrance in retinitis pigmentosa. (26781568)
2016
50
Clinical presentation and visual status of retinitis pigmentosa patients: a multicenter study in southwestern Nigeria. (27601870)
2016

Variations for Retinitis Pigmentosa

About this section

UniProtKB/Swiss-Prot genetic disease variations for Retinitis Pigmentosa:

70
id Symbol AA change Variation ID SNP ID
1CRXp.Arg41GlnVAR_007946rs61748436

Clinvar genetic disease variations for Retinitis Pigmentosa:

5 (show all 108)
id Gene Variation Type Significance SNP ID Assembly Location
1RHONM_ 000539.3(RHO): c.403C> T (p.Arg135Trp)SNVPathogenicrs104893775GRCh37Chr 3, 129249760: 129249760
2RHONM_ 000539.3(RHO): c.44A> G (p.Asn15Ser)SNVPathogenicrs104893786GRCh37Chr 3, 129247620: 129247620
3PDE6BNM_ 000283.3(PDE6B): c.1669C> T (p.His557Tyr)SNVPathogenicrs121918581GRCh37Chr 4, 655977: 655977
4RPE65NM_ 000329.2(RPE65): c.1543C> T (p.Arg515Trp)SNVPathogenicrs121917745GRCh37Chr 1, 68895518: 68895518
5MYO7ANM_ 000260.3(MYO7A): c.1667G> T (p.Gly556Val)SNVLikely pathogenicrs527236085GRCh38Chr 11, 77162965: 77162965
6PDE6BNM_ 000283.3(PDE6B): c.1467+1G> CSNVPathogenicrs527236089GRCh37Chr 4, 652807: 652807
7PDE6BNM_ 000283.3(PDE6B): c.1576G> A (p.Glu526Lys)SNVLikely pathogenicrs527236091GRCh37Chr 4, 654364: 654364
8PDE6BNM_ 000283.3(PDE6B): c.1604T> A (p.Ile535Asn)SNVPathogenicrs527236088GRCh37Chr 4, 654392: 654392
9PDE6BNM_ 000283.3(PDE6B): c.993-1G> CSNVLikely pathogenicrs527236090GRCh37Chr 4, 649728: 649728
10PRPH2NM_ 000322.4(PRPH2): c.410G> A (p.Gly137Asp)SNVPathogenicrs527236097GRCh37Chr 6, 42689663: 42689663
11PRPH2NM_ 000322.4(PRPH2): c.499G> A (p.Gly167Ser)SNVPathogenic/ Likely pathogenicrs527236098GRCh37Chr 6, 42689574: 42689574
12ROM1NM_ 000327.3(ROM1): c.331dupG (p.Leu114Alafs)duplicationPathogenicrs527236104GRCh38Chr 11, 62613612: 62613612
13RHONM_ 000539.3(RHO): c.180C> A (p.Tyr60Ter)SNVLikely pathogenicrs527236101GRCh37Chr 3, 129247756: 129247756
14RHONM_ 000539.3(RHO): c.520G> A (p.Gly174Ser)SNVPathogenicrs527236103GRCh37Chr 3, 129249877: 129249877
15RHONM_ 000539.3(RHO): c.562G> A (p.Gly188Arg)SNVPathogenicrs527236100GRCh37Chr 3, 129251125: 129251125
16RHONM_ 000539.3(RHO): c.977_ 980delACCC (p.Pro327Trpfs)deletionLikely pathogenicrs527236102GRCh37Chr 3, 129252491: 129252494
17CRXNM_ 000554.5(CRX): c.193G> C (p.Asp65His)SNVPathogenicrs527236062GRCh38Chr 19, 47836335: 47836335
18CRXNM_ 000554.5(CRX): c.897G> C (p.Leu299Phe)SNVLikely pathogenicrs527236063GRCh38Chr 19, 47839964: 47839964
19C2orf71NM_ 001029883.2(C2orf71): c.2126delG (p.Gly709Glufs)deletionLikely pathogenicrs527236055GRCh37Chr 2, 29295002: 29295002
20C2orf71NM_ 001029883.2(C2orf71): c.2988dupC (p.Thr997Hisfs)duplicationLikely pathogenicrs527236056GRCh37Chr 2, 29294140: 29294140
21RPGRNM_ 001034853.1(RPGR): c.1087_ 1088insGTAG (p.Val363Glyfs)insertionLikely pathogenicrs527236109GRCh37Chr X, 38158366: 38158367
22RPGRNM_ 001034853.1(RPGR): c.1981G> T (p.Glu661Ter)SNVLikely pathogenicrs527236108GRCh37Chr X, 38146271: 38146271
23RPGRNM_ 000328.2(RPGR): c.894_ 895delTT (p.Ser298Argfs)deletionLikely pathogenicrs527236111GRCh37Chr X, 38163927: 38163928
24RPGRNM_ 001034853.1(RPGR): c.922G> C (p.Ala308Pro)SNVLikely pathogenicrs527236112GRCh37Chr X, 38163900: 38163900
25PRCDNM_ 001077620.2(PRCD): c.2T> C (p.Met1Thr)SNVPathogenicrs527236092GRCh37Chr 17, 74536225: 74536225
26CNGA1NM_ 001142564.1(CNGA1): c.1046G> A (p.Arg349His)SNVLikely pathogenicrs375412499GRCh37Chr 4, 47939672: 47939672
27CNGA1NM_ 001142564.1(CNGA1): c.1196A> G (p.Asp399Gly)SNVLikely pathogenicrs527236059GRCh37Chr 4, 47939522: 47939522
28CNGA1NM_ 001142564.1(CNGA1): c.1840G> A (p.Gly614Ser)SNVLikely pathogenicrs527236057GRCh37Chr 4, 47938878: 47938878
29CNGA1NM_ 001142564.1(CNGA1): c.398delG (p.Gly133Valfs)deletionLikely pathogenicrs527236058GRCh37Chr 4, 47953415: 47953415
30EYSNM_ 001142800.1(EYS): c.1345A> T (p.Lys449Ter)SNVLikely pathogenicrs527236077GRCh37Chr 6, 66063465: 66063465
31EYSNM_ 001142800.1(EYS): c.1750G> T (p.Glu584Ter)SNVLikely pathogenicrs527236072GRCh37Chr 6, 66044889: 66044889
32EYSNM_ 001142800.1(EYS): c.4387delA (p.Arg1463Glyfs)deletionLikely pathogenicrs527236075GRCh37Chr 6, 65301373: 65301373
33EYSNM_ 001142800.1(EYS): c.4402_ 4403insTCAAGAGG (p.Asp1468Valfs)insertionLikely pathogenicrs527236073GRCh37Chr 6, 65301357: 65301358
34EYSNM_ 001142800.1(EYS): c.4957dupA (p.Ser1653Lysfs)duplicationPathogenicrs527236065GRCh38Chr 6, 64590910: 64590910
35EYSNM_ 001142800.1(EYS): c.5014C> T (p.Gln1672Ter)SNVLikely pathogenicrs527236074GRCh37Chr 6, 65300746: 65300746
36EYSNM_ 001142800.1(EYS): c.5202_ 5203delGT (p.Phe1735Glnfs)deletionLikely pathogenicrs527236071GRCh37Chr 6, 65300557: 65300558
37EYSNM_ 001142800.1(EYS): c.6557G> A (p.Gly2186Glu)SNVPathogenicrs527236068GRCh37Chr 6, 64791763: 64791763
38EYSNM_ 001142800.1(EYS): c.7048delT (p.Cys2350Alafs)deletionLikely pathogenicrs527236069GRCh37Chr 6, 64694283: 64694283
39EYSNM_ 001142800.1(EYS): c.7694delA (p.Asn2565Metfs)deletionLikely pathogenicrs527236078GRCh37Chr 6, 64498027: 64498027
40EYSNM_ 001142800.1(EYS): c.7793G> A (p.Gly2598Asp)SNVPathogenicrs527236064GRCh37Chr 6, 64488004: 64488004
41EYSNM_ 001142800.1(EYS): c.7919G> A (p.Trp2640Ter)SNVPathogenicrs527236066GRCh37Chr 6, 64472506: 64472506
42EYSNM_ 001142800.1(EYS): c.8012T> A (p.Leu2671Ter)SNVLikely pathogenicrs527236076GRCh37Chr 6, 64472413: 64472413
43EYSNM_ 001142800.1(EYS): c.8379_ 8380insTGCA (p.Glu2794Cysfs)insertionLikely pathogenicrs527236070GRCh37Chr 6, 64431547: 64431548
44EYSNM_ 001142800.1(EYS): c.8805C> A (p.Tyr2935Ter)SNVPathogenicrs527236067GRCh37Chr 6, 64431122: 64431122
45EYSNM_ 001142800.1(EYS): c.9209T> C (p.Ile3070Thr)SNVPathogenicrs183589498GRCh37Chr 6, 64430718: 64430718
46MAKNM_ 001242385.1(MAK): c.340dupG (p.Ala114Glyfs)duplicationLikely pathogenicrs527236082GRCh37Chr 6, 10813895: 10813895
47MAKNM_ 001242385.1(MAK): c.496C> T (p.Arg166Cys)SNVLikely pathogenicrs527236081GRCh37Chr 6, 10804120: 10804120
48MAKNM_ 001242385.1(MAK): c.553G> A (p.Ala185Thr)SNVLikely pathogenicrs527236080GRCh37Chr 6, 10804063: 10804063
49CNGB1NM_ 001297.4(CNGB1): c.217+5G> CSNVLikely pathogenicrs527236060GRCh38Chr 16, 57964482: 57964482
50CNGB1NM_ 001297.4(CNGB1): c.2524dupA (p.Thr842Asnfs)duplicationLikely pathogenicrs527236061GRCh38Chr 16, 57904844: 57904844
51TULP1NM_ 003322.5(TULP1): c.349G> A (p.Glu117Lys)SNVLikely pathogenicrs527236117GRCh37Chr 6, 35479425: 35479425
52BEST1NM_ 004183.3(BEST1): c.763C> T (p.Arg255Trp)SNVPathogenicrs372989281GRCh38Chr 11, 61958194: 61958194
53LRATNM_ 004744.4(LRAT): c.163C> T (p.Arg55Trp)SNVLikely pathogenicrs527236079GRCh37Chr 4, 155665641: 155665641
54TOPORSNM_ 005802.4(TOPORS): c.2554_ 2557delGAGA (p.Glu852Glnfs)deletionPathogenicrs527236116GRCh37Chr 9, 32541966: 32541969
55NRLNM_ 006177.3(NRL): c.23delT (p.Leu8Argfs)deletionLikely pathogenicrs527236087GRCh37Chr 14, 24552035: 24552035
56RP1NM_ 006269.1(RP1): c.1186C> T (p.Arg396Ter)SNVLikely pathogenicrs201493928GRCh37Chr 8, 55537628: 55537628
57RP1NM_ 006269.1(RP1): c.4876G> A (p.Gly1626Arg)SNVLikely pathogenicrs527236106GRCh37Chr 8, 55541318: 55541318
58RP1NM_ 006269.1(RP1): c.5797C> T (p.Arg1933Ter)SNVLikely pathogenicrs118031911GRCh37Chr 8, 55542239: 55542239
59RP1NM_ 006269.1(RP1): c.649delG (p.Gly217Glufs)deletionLikely pathogenicrs527236105GRCh37Chr 8, 55534710: 55534710
60MERTKNM_ 006343.2(MERTK): c.1450G> A (p.Gly484Ser)SNVLikely pathogenicrs527236084GRCh37Chr 2, 112751981: 112751981
61MERTKNM_ 006343.2(MERTK): c.225delA (p.Gly76Glufs)deletionLikely pathogenicrs527236083GRCh37Chr 2, 112686860: 112686860
62PRPF6NM_ 012469.3(PRPF6): c.550G> C (p.Asp184His)SNVLikely pathogenicrs527236096GRCh37Chr 20, 62626380: 62626380
63SNRNP200NM_ 014014.4(SNRNP200): c.2042G> A (p.Arg681His)SNVPathogenicrs527236113GRCh37Chr 2, 96958828: 96958828
64SNRNP200NM_ 014014.4(SNRNP200): c.2047G> T (p.Val683Leu)SNVPathogenicrs527236114GRCh37Chr 2, 96958823: 96958823
65NR2E3NM_ 014249.3(NR2E3): c.364C> T (p.Arg122Cys)SNVLikely pathogenicrs527236086GRCh38Chr 15, 71811969: 71811969
66PRPF31NM_ 015629.3(PRPF31): c.562G> T (p.Glu188Ter)SNVLikely pathogenicrs527236094GRCh38Chr 19, 54123783: 54123783
67PRPF31NM_ 015629.3(PRPF31): c.615C> G (p.Tyr205Ter)SNVLikely pathogenicrs144738703GRCh38Chr 19, 54123836: 54123836
68PRPF31NM_ 015629.3(PRPF31): c.764A> T (p.Gln255Leu)SNVLikely pathogenicrs527236095GRCh38Chr 19, 54124565: 54124565
69IMPG2NM_ 016247.3(IMPG2): c.3262C> T (p.Arg1088Ter)SNVPathogenicrs199867882GRCh37Chr 3, 100949961: 100949961
70RDH12NM_ 152443.2(RDH12): c.776delG (p.Glu260Argfs)deletionPathogenicrs527236099GRCh37Chr 14, 68196025: 68196025
71RP1L1NM_ 178857.5(RP1L1): c.1972C> T (p.Arg658Ter)SNVLikely pathogenicrs527236107GRCh37Chr 8, 10469636: 10469636
72RP1L1NM_ 178857.5(RP1L1): c.235C> T (p.Arg79Cys)SNVLikely pathogenicrs377269054GRCh37Chr 8, 10480477: 10480477
73USH2ANM_ 206933.2(USH2A): c.10544A> G (p.Asp3515Gly)SNVPathogenicrs527236119GRCh37Chr 1, 215956121: 215956121
74USH2ANM_ 206933.2(USH2A): c.13466G> A (p.Gly4489Asp)SNVLikely pathogenicrs527236127GRCh37Chr 1, 215847787: 215847787
75USH2ANM_ 206933.2(USH2A): c.13847G> T (p.Gly4616Val)SNVLikely pathogenicrs527236124GRCh37Chr 1, 215844600: 215844600
76USH2ANM_ 206933.2(USH2A): c.14450G> A (p.Gly4817Glu)SNVLikely pathogenicrs527236125GRCh37Chr 1, 215822002: 215822002
77USH2ANM_ 206933.2(USH2A): c.15233C> G (p.Pro5078Arg)SNVPathogenicrs527236122GRCh37Chr 1, 215807865: 215807865
78USH2ANM_ 206933.2(USH2A): c.1722_ 1723insGA (p.Cys575Aspfs)insertionLikely pathogenicrs527236121GRCh37Chr 1, 216465634: 216465635
79USH2ANM_ 206933.2(USH2A): c.2802T> G (p.Cys934Trp)SNVPathogenicrs201527662GRCh37Chr 1, 216419934: 216419934
80USH2ANM_ 206933.2(USH2A): c.490G> T (p.Val164Phe)SNVLikely pathogenicrs527236123GRCh37Chr 1, 216592017: 216592017
81USH2ANM_ 206933.2(USH2A): c.6399G> A (p.Trp2133Ter)SNVLikely pathogenicrs55958016GRCh37Chr 1, 216173831: 216173831
82USH2ANM_ 206933.2(USH2A): c.8682delG (p.Arg2894Serfs)deletionLikely pathogenicrs527236120GRCh37Chr 1, 216040512: 216040512
83USH2ANM_ 206933.2(USH2A): c.9751T> C (p.Cys3251Arg)SNVPathogenicrs527236118GRCh37Chr 1, 215972456: 215972456
84PDE6BNM_ 000283.3(PDE6B): c.2193+1G> ASNVPathogenicrs727504075GRCh37Chr 4, 658734: 658734
85RPGRNM_ 001034853.1(RPGR): c.2426_ 2427delAG (p.Glu809Glyfs)deletionPathogenicrs730882261GRCh37Chr X, 38145825: 38145826
86ABCA4NM_ 000350.2(ABCA4): c.2927delT (p.Leu976Argfs)deletionPathogenicrs863223338GRCh38Chr 1, 94044736: 94044736
87PDE6BNM_ 000283.3(PDE6B): c.1060-1G> TSNVPathogenicrs863223339GRCh37Chr 4, 650033: 650033
88RP1NM_ 006269.1(RP1): c.679T> G (p.Phe227Val)SNVPathogenicrs863223340GRCh37Chr 8, 55534740: 55534740
89IFT140NM_ 014714.3(IFT140): c.3827G> A (p.Gly1276Glu)SNVPathogenicrs779007169GRCh38Chr 16, 1520177: 1520177
90CRB1NM_ 001257965.1(CRB1): c.2711G> A (p.Cys904Tyr)SNVPathogenicrs863223341GRCh37Chr 1, 197398685: 197398685
91CRB1NM_ 001257965.1(CRB1): c.1252dupT (p.Ser418Phefs)duplicationPathogenicrs863223342GRCh38Chr 1, 197421287: 197421287
92PANK2NM_ 024960.5(PANK2): c.419T> C (p.Phe140Ser)SNVPathogenicrs863223343GRCh38Chr 20, 3912514: 3912514
93C2orf71NM_ 001029883.2(C2orf71): c.712A> T (p.Lys238Ter)SNVPathogenicrs863223344GRCh37Chr 2, 29296416: 29296416
94RDH12NM_ 152443.2(RDH12): c.377C> T (p.Ala126Val)SNVPathogenicrs202126574GRCh37Chr 14, 68192801: 68192801
95PDE6BNM_ 000283.3(PDE6B): c.291C> A (p.Tyr97Ter)SNVPathogenic/ Likely pathogenicrs876657718GRCh37Chr 4, 619706: 619706
96USH2ANM_ 206933.2(USH2A): c.2299delG (p.Glu767Serfs)deletionPathogenicrs80338903GRCh37Chr 1, 216420437: 216420437
97USH2ANM_ 206933.2(USH2A): c.14020A> G (p.Arg4674Gly)SNVPathogenicrs80338904GRCh37Chr 1, 215844427: 215844427
98RCBTB1NM_ 018191.3(RCBTB1): c.919G> A (p.Val307Met)SNVPathogenic/ Likely pathogenicrs368217569GRCh37Chr 13, 50123720: 50123720
99RCBTB1NM_ 018191.3(RCBTB1): c.930G> T (p.Trp310Cys)SNVPathogenic/ Likely pathogenicrs772592456GRCh37Chr 13, 50123709: 50123709
100RCBTB1NM_ 018191.3(RCBTB1): c.973C> T (p.His325Tyr)SNVPathogenic/ Likely pathogenicrs200826424GRCh37Chr 13, 50123666: 50123666
101RCBTB1NM_ 018191.3(RCBTB1): c.1164G> T (p.Leu388Phe)SNVPathogenic/ Likely pathogenicrs879255547GRCh37Chr 13, 50118881: 50118881
102IMPDH1NM_ 000883.3(IMPDH1): c.928A> C (p.Thr310Pro)SNVLikely pathogenicrs1057518949GRCh37Chr 7, 128038614: 128038614
103USH2ANM_ 206933.2(USH2A): c.8559-2A> GSNVPathogenicrs397518039GRCh37Chr 1, 216051224: 216051224
104UNC119NM_ 005148.3(UNC119): c.169A> T (p.Lys57Ter)SNVPathogenicrs267607166GRCh37Chr 17, 26879407: 26879407
105TULP1NM_ 003322.5(TULP1): c.1145T> C (p.Phe382Ser)SNVPathogenicrs121909076GRCh37Chr 6, 35471593: 35471593
106PRPH2NM_ 000322.4(PRPH2): c.736T> C (p.Trp246Arg)SNVPathogenicrs61755817GRCh37Chr 6, 42672195: 42672195
107RPGRNM_ 000328.2(RPGR): c.469+1G> ASNVLikely pathogenicrs62638646GRCh37Chr X, 38178081: 38178081
108RPE65NM_ 000329.2(RPE65): c.118G> A (p.Gly40Ser)SNVPathogenicrs61751281GRCh37Chr 1, 68912520: 68912520

Copy number variations for Retinitis Pigmentosa from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
156866116170000063400000Gain or lossROM1Retinitis pigmentosa
2132542195931064859326954MicrodeletionPRPF31Retinitis pigmentosa
3179965414500000Copy numberPDE6BRetinitis pigmentosa
421478766609589166473839DeletionEYSRetinitis pigmentosa
52194657127100000129200000Gain or lossIMPDH1Retinitis pigmentosa

Expression for genes affiliated with Retinitis Pigmentosa

About this section
Search GEO for disease gene expression data for Retinitis Pigmentosa.

Pathways for genes affiliated with Retinitis Pigmentosa

About this section

GO Terms for genes affiliated with Retinitis Pigmentosa

About this section

Cellular components related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1photoreceptor outer segmentGO:000175011.5ABCA4, C2orf71, PRCD, PRPH2, RHO, RP1
2photoreceptor inner segmentGO:000191711.4C2orf71, RHO, RP1, TULP1, USH2A
3ciliumGO:000592911.4C2orf71, RP1, RPGR, TULP1
4ciliary basal bodyGO:003606411.4RPGR, TOPORS, USH2A
5photoreceptor connecting ciliumGO:003239111.3RP1, TOPORS, USH2A
6photoreceptor disc membraneGO:009738111.3ABCA4, PDE6B, RHO
7photoreceptor inner segment membraneGO:006034211.1RDH12, RHO
8photoreceptor outer segment membraneGO:004262210.7RHO, ROM1

Biological processes related to Retinitis Pigmentosa according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1response to stimulusGO:005089612.3ABCA4, BEST1, C2orf71, CRX, EYS, PDE6B
2visual perceptionGO:000760112.0ABCA4, BEST1, C2orf71, CRX, EYS, IMPG2
3photoreceptor cell maintenanceGO:004549411.7ABCA4, RDH12, RHO, RP1, TULP1, USH2A
4retina development in camera-type eyeGO:006004111.6PDE6B, PRPH2, RHO, RP1, RPE65, TULP1
5phototransduction, visible lightGO:000760311.5ABCA4, PDE6B, RHO, RP1
6detection of light stimulus involved in visual perceptionGO:005090811.5BEST1, EYS, RPE65, TULP1
7photoreceptor cell outer segment organizationGO:003584511.4C2orf71, RP1, TOPORS
8retinoid metabolic processGO:000152311.4ABCA4, RDH12, RHO, RPE65
9cellular response to light stimulusGO:007148211.4RHO, RP1
10detection of light stimulusGO:000958311.4PDE6B, RHO
11retina morphogenesis in camera-type eyeGO:006004211.4ROM1, RP1, RPE65
12eye photoreceptor cell developmentGO:004246211.4CRB1, TULP1
13regulation of rhodopsin mediated signaling pathwayGO:002240011.4PDE6B, RHO
14response to light stimulusGO:000941611.3RHO, RPE65
15protein localization to photoreceptor outer segmentGO:190354611.3C2orf71, TULP1
16retinal cone cell developmentGO:004654911.3RP1, TOPORS
17retinal rod cell developmentGO:004654811.3RP1, TOPORS
18rhodopsin mediated signaling pathwayGO:001605611.2PDE6B, RHO
19sensory perception of light stimulusGO:005095311.2RHO, USH2A

Sources for Retinitis Pigmentosa

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet